A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes

Exclusion Criteria

• •MDS evolving from a pre-existing myeloproliferative neoplasm (MPN), myelodysplastic/myeloproliferative neoplasms (MDS/MPN).
• •Prior treatment with Cluster of Differentiation (CD) 47 or Signal-regulatory protein alpha (SIRPα)-targeting agents.
• •Concurrently participating in another interventional clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study.
• •Patients who previously diagnosed with another malignancy and have any evidence of residual disease.
• •Known allergy to any component of any study drug; known history of severe hypersensitivity to other monoclonal antibodies.
• •Patients with any psychiatric or social factor which the investigator deems may interfere with the patient's ability to comply with the requirements of the study.
• •Patients with current hypertension with systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg after oral antihypertensive therapy.
• •Patients with known cardiopulmonary disease defined as unstable angina, clinically significant arrhythmia, congestive heart failure (New York Heart Association Class III or IV), decompensated cirrhosis, nephrotic syndrome, uncontrolled metabolic disorders.
• •Patients who are breastfeeding or plans to breastfeed during the study.
• •Other conditions where the investigator considers the patient inappropriate for enrollment.